Roles of C-reactive protein and LOX-1 on cancer and myeloid-derived suppressor cells in the progression of uterine cervical cancer

  • 0Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.

|

|

Summary

This summary is machine-generated.

Elevated C-reactive protein (CRP) levels worsen outcomes in cervical cancer patients with LOX-1 expressing tumors, indicating CRP and LOX-1 as potential therapeutic targets.

Area Of Science

  • Oncology
  • Immunology
  • Biochemistry

Background

  • C-reactive protein (CRP) is an inflammatory marker.
  • The receptor LOX-1 (lectin-like oxidized LDL receptor 1) role in cancer is emerging.
  • Understanding CRP and LOX-1 interplay in cervical cancer is crucial for treatment.

Purpose Of The Study

  • To investigate the clinical significance of CRP and LOX-1 in cervical cancer progression.
  • To elucidate the mechanisms by which CRP promotes cervical cancer via LOX-1.

Main Methods

  • Analysis of clinical data from 121 cervical cancer patients treated with radiotherapy.
  • In vitro studies using cervical cancer cell lines.
  • In vivo studies using mouse xenograft models.
  • Assessment of CRP levels, LOX-1 expression, and patient survival.

Main Results

  • Elevated pretreatment CRP levels correlated with shorter overall survival in patients with LOX-1-expressing tumors.
  • CRP promoted proliferation and progression of LOX-1-expressing cervical cancer cells in vitro and in vivo.
  • CRP enhanced myeloid-derived suppressor cell (MDSC) survival and suppressive function.
  • CRP's tumor-promoting effects were minimal in tumors lacking LOX-1 expression.

Conclusions

  • CRP facilitates the progression of LOX-1-expressing cervical cancer by activating LOX-1 signaling in cancer cells and MDSCs.
  • Targeting CRP or LOX-1 presents a potential therapeutic strategy for LOX-1-expressing cervical cancers.